UK markets open in 6 hours 5 minutes
NIKKEI 225
38,798.44 -124.59 (-0.32%) HANG SENG
18,403.04 +323.43 (+1.79%) CRUDE OIL
74.02 -0.20 (-0.27%) GOLD FUTURES
2,372.70 +3.40 (+0.14%) DOW
38,571.03 -115.29 (-0.30%) Bitcoin GBP
53,905.70 +963.98 (+1.82%)
Denali Therapeutics Inc. (DNLI)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 18.56 |
| Open | 18.91 |
| Bid | 20.36 x 300 |
| Ask | 20.45 x 100 |
| Day's range | 18.81 - 20.42 |
| 52-week range | 14.56 - 33.31 |
| Volume | |
| Avg. volume | 1,083,601 |
| Market cap | 2.906B |
| Beta (5Y monthly) | 1.39 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.94 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 39.69 |
GlobeNewswireDenali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
START is a pilot program newly launched jointly by the FDA CDER and CBER divisions to further accelerate the development of novel drug and biological products for rare diseasesDNL126 was selected as one of three CDER-regulated products based on eligibility criteria including the potential for clinical benefit for a rare neurodegenerative disease and the drug sponsor’s ability to advance development towards a marketing application Participation in START is expected to facilitate and accelerate de
Simply Wall St.The Consensus EPS Estimates For Denali Therapeutics Inc. (NASDAQ:DNLI) Just Fell Dramatically
The latest analyst coverage could presage a bad day for Denali Therapeutics Inc. ( NASDAQ:DNLI ), with the analysts...
Simply Wall St.Denali Therapeutics First Quarter 2024 Earnings: US$0.68 loss per share (vs US$0.80 loss in 1Q 2023)
Denali Therapeutics ( NASDAQ:DNLI ) First Quarter 2024 Results Key Financial Results Net loss: US$101.8m (loss narrowed...
© 2024 Yahoo. All rights reserved.